Johnson & Johnson

Oncology

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

News

Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.

News

A drug at the heart of Johnson & Johnson's $3bn takeover of Halda has been shown to be "highly active" in a first-in-human prostate cancer trial.

News

Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.

News

The FDA has handed ImmunityBio a key label extension for bladder cancer therapy Anktiva, giving it a leg-up on rival drug Inlexzo from J&J.

News

The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).